Pharma & Biotech

Legend Biotech has confirmed that chief executive Ying Huang, Ph.D., has stepped down after six years leading the company. Alan Bash, who has served as president of Carvykti since 2024, will take

Novo Nordisk has filed a lawsuit against rival Eli Lilly (LLY), accusing the US drugmaker of running “false and misleading” advertisements for its obesity drug Zepbound. The legal clash between two of

Pharmaceutical supply chains face mounting pressure to maintain precise product traceability at every stage of the distribution process. Aggregation, the process of linking serialised items to their parent containers, has emerged as

Karyopharm Therapeutics has suffered a severe blow after its flagship drug selinexor, sold as Xpovio, failed to meet its primary endpoint in a Phase 3 endometrial cancer trial. The XPORT-EC-042 trial evaluated

The pharmaceutical supply chain faces a persistent challenge: being “GS1-aligned” does not always mean a system has been independently validated against the standard. GS1 certification is emerging as a critical distinction for

Pharmaceutical and biotech companies are under mounting pressure to justify artificial intelligence investments, but the harder question is whether anyone is measuring if it actually works. A recent market survey of brand

Daiichi Sankyo has revised its full-year guidance upward after discovering an accounting error that understated operating profit in its fiscal year 2025 results. The Japanese pharmaceutical company identified a mistake in the

The pharmaceutical industry continues to wrestle with supply chain vulnerability, a problem that has intensified steadily since pandemic-era drug shortages first exposed critical weaknesses. Geopolitical tensions, tariff uncertainty, and ongoing national security

STEPLogic Trace is positioning itself as a key solution for pharmaceutical companies navigating the complex requirements of DSCSA-compliant supply chains. The platform helps pharmaceutical supply chains produce certified EPCIS outputs, enabling companies

Alnylam Pharmaceuticals (ALNY) shares collapsed nearly 28% on Thursday, closing at $206.88 after the company reported disappointing Amvuttra sales and slashed its full-year outlook. The RNA interference therapy crossed the $1 billion